Accuracy of B-Type Natriuretic Peptide Tests to Exclude Congestive Heart Failure
Open Access
- 22 May 2006
- journal article
- review article
- Published by American Medical Association (AMA) in Archives of Internal Medicine
- Vol. 166 (10), 1073-1080
- https://doi.org/10.1001/archinte.166.10.1073
Abstract
Congestive heart failure (CHF) is a major public health problem. Incidence and prevalence of CHF increase steeply with age,1,2 and CHF is a leading cause of hospitalization among people older than 65 years.3,4 With improvements in the prognosis of CHF, improved survival after acute myocardial infarction, and an aging population, the burden of CHF will continue to increase in the years to come.3Keywords
This publication has 35 references indexed in Scilit:
- Measuring inconsistency in meta-analysesBMJ, 2003
- B-type natriuretic peptide in the diagnosis of cardiac disease in elderly day hospital patientsAge and Ageing, 2002
- Clinical Significance of Brain Natriuretic Peptide in Patients with Postmyocardial InfarctionClinical Cardiology, 2000
- Randomised comparisons of medical tests: sometimes invalid, not always efficientThe Lancet, 2000
- Biochemical detection of left-ventricular systolic dysfunctionThe Lancet, 1998
- Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban populationThe Lancet, 1997
- Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunctionThe American Journal of Cardiology, 1996
- Detection of left ventricular dysfunction after acute myocardial infarction: comparison of clinical, echocardiographic, and neurohormonal methods.Heart, 1994
- Plasma brain natriuretic peptide in assessment of acute dyspnoeaThe Lancet, 1994
- Combining independent studies of a diagnostic test into a summary roc curve: Data‐analytic approaches and some additional considerationsStatistics in Medicine, 1993